Skip to content

The Effects of KSM-66 Ashwagandha Supplementation on Recovery and Muscle Strength in Academy Athletes

The Effects of KSM-66 Ashwagandha (Withania Somnifera) Supplementation on Recovery and Muscle Strength in Academy Athletes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07041853
Enrollment
56
Registered
2025-06-27
Start date
2025-06-12
Completion date
2025-08-25
Last updated
2025-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exercise Training, Recovery, Strength

Keywords

ashwagandha, athlete, recovery, performance, cortisol

Brief summary

This double-blind, randomised, placebo-controlled trial will examine the effects of 42-day root extract ashwagandha (KSM-66) supplementation on recovery and muscle strength in male and female rugby and water polo players. Participants will receive either 600 mg of ashwagandha or a placebo daily. Outcomes include hormonal stress markers, perceived exertion, wellness, muscle soreness and strength and performance metrics (grip strength, jump tests, 1RM lifts, Bronco test).

Detailed description

This double-blind, randomised, placebo-controlled trial aims to investigate the effects of ashwagandha (ASH) supplementation on recovery and muscle strength in male and female rugby and water polo players. Participants will supplement either KSM-66 ashwagandha (600 mg, standardised to 5% withanolides) or a placebo once daily for 42 days. The study will evaluate outcomes related to hormonal stress markers, perceived exertion, wellness, muscle soreness, and physical performance. Primary biomarkers include cortisol, DHEA-S, testosterone, melatonin, alpha-amylase, and cortisone, assessed through saliva samples. Subjective measures will include the Borg Rate of Perceived Exertion Scale and the Hooper Index for sleep quality, stress, fatigue, and delayed onset muscle soreness (DOMS). Physical performance will be assessed using grip strength (CAMRY dynamometer), vertical jump tests (countermovement jump, squat jump), broad jump, 1-repetition maximum (1RM) tests for deadlift, bench press, and pull-up, as well as the Bronco test. Supplement satisfaction will be evaluated via questionnaire. Participants' dietary intake will be recorded using a self-tracking method (Snap-N-Send) and analysed using Nutritics software; food diaries will serve as covariates in the final analysis. The study will be conducted in partnership with CN Poble Nou, a professional sports club in Barcelona, Spain. Ashwagandha use is increasingly common among athletes despite limited evidence on appropriate dosing and performance outcomes. This study will contribute to scientific understanding of its potential short-term benefits, particularly in high-contact sports where managing cortisol and recovery is critical. All participants will provide informed consent, and ethical considerations focus on safety, data privacy, and the right to withdraw from the study at any time.

Interventions

DIETARY_SUPPLEMENTKSM-66 Ashwagandha

Root extract ashwagandha, KSM-66

DIETARY_SUPPLEMENTPlacebo

Organic chickpea flour

Sponsors

University Ramon Llull
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Above the age of 18 * Healthy and free of disease * Assigned as an athlete at CN Poble Nou sports academy

Exclusion criteria

* Allergies to nightshades such as tomato, aubergine, potatoes and peppers * Active supplementation with other ergogenic aids (to not interfere with existing treatment) * Medication or contraceptives (to not interfere with existing treatment) * Liver conditions (to not interfere with existing treatment) * Thyroid conditions (to not interfere with existing treatment) * Diabetes or certain autoimmune conditions (to not interfere with existing treatment) * Active pregnancy (to not interfere with existing treatment) * No signing of the consent form

Design outcomes

Primary

MeasureTime frameDescription
CortisolBaseline and final measurement at 6 weeksSalivary cortisol
Hand gripBaseline and final measurement at 6 weeksHand grip strength in kilograms, CAMRY dynanometer

Secondary

MeasureTime frameDescription
DHEA-sBaseline and final measurement at 6 weeksSalivary DHEA-s
Alpha-amylaseBaseline and final measurement at 6 weeksSalivary alpha-amylase
TestosteroneBaseline and final measurement at 6 weeksSalivary testosterone
Bronco testBaseline and final measurement at 6 weeksAerobic fitness test in minutes and seconds
CortisoneBaseline and final measurement at 6 weeksSalivary cortisone
MelatoninBaseline and final measurement at 6 weeksSalivary melatonin

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026